Arcus will now refocus its efforts outside of TIGIT, specifically on its asset casdatifan, an HIF-2a inhibitor once backed by Gilead, as well as its earlier stage small-molecule inflammatory and ...

Non-opioid analgesic shows efficacy in several animal pain models, including diabetic and chemotherapy-induced neuropathic ...

Non-opioid analgesic shows efficacy in several animal pain models, including diabetic and chemotherapy-induced neuropathic pain Compelling safety and pharmacokinetic profiles in animals support IND-en ...

HanchorBio Announces Oral Presentation of HCB101 at the ESMO Immuno-Oncology Congress 2025 ...

Discusses Year-End Late-Stage Pipeline Review With Focus on Clinical and Regulatory Developments December 16, 2025 11:15 AM ...

Researchers at Karolinska Institutet have identified small molecules capable of influencing a hard-to-target receptor family ...

One of the most exciting advances in cancer treatments in the past decade is the development of T cell immunotherapies, in which a patient's own immune system is trained to recognize and attack ...

A hidden “jack-in-the-box” mechanism inside T cells may hold the key to unlocking more powerful cancer immunotherapies.

This study investigates the molecular mechanisms underlying ligand recognition, subtype selectivity, and activation of ...

One of the most exciting advances in cancer treatments in the past decade is the development of T cell immunotherapies, in which a patient's own immune system is trained to recognize and attack ...

Neurocrine Biosciences, Inc. ( NBIX) Discusses Progress and Strategy in Neurology and Obesity R&D Programs December 16, 2025 12:00 PM EST ...

African Swine Fever Virus, ASFV, Viral Entry, Host Cell Invasion, CD163, Siglec-1, Macropinocytosis, Endosomal Escape, Immune Evasion, Signaling Pathways Share and Cite: Marcelino, K.B. and Fang, G.J.